Jump to content

Zometa to protect bones reduces skeletal related events, extends life


Recommended Posts

The Benefits Of Timely Intervention With Zoledronic Acid In Patients With Metastatic Prostate Cancer To Bones: A Retrospective Study Of The US Veterans Affairs Population - Abstract

Article base category

Written by Lynda Coghlan

Saturday, 29 January 2011 10:51

Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA.

Section of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.

To examine the effect of timely zoledronic acid (ZA) treatment on clinical outcomes and health care utilization in patients with bone-metastatic prostate cancer. Patients with prostate cancer and bone metastasis were identified in a Veterans Affairs database (01/2002-09/2009). Eligible patients had no documented skeletal-related events (SREs) before the index date (that is, the first bone metastasis diagnosis date). Patients who received early ZA treatment, defined as having a ZA infusion after the index date and before any recorded SREs, were matched 1:1 on propensity score to patients not treated with bisphosphonates (BPs). Risks of SREs, hospitalization and death during the 6-month post-index period were compared between matched cohorts using Kaplan-Meier analyses. Baseline characteristics were well balanced between the matched cohorts (n=73 per group). 6-month SRE-free survival and hospitalization-free survival were higher in patients receiving timely ZA than patients without BP treatment (91.7 versus 71.5%, P< 0.01; 80.5 versus 66.3%, P=0.05, respectively). 6-month mortality risk was significantly lower in patients treated with ZA versus those without BP treatment (4.3 versus 13.8%, P=0.04). Timely ZA intervention in bone-metastatic prostate cancer patients was associated with significant reductions in 6-month risks of SREs, hospitalization and mortality, as compared with no BP treatment.

Written by:

Velde NV, Wu EQ, Guo A, Lu M, Yu AP, Sharma H, Liu J, Fan CP, Shi L.

Reference: Prostate Cancer Prostatic Dis. 2010 Dec 21. Epub ahead of print.

doi: 10.1038/pcan.2010.49

PubMed Abstract

PMID: 21173792 Forum: Metastatic prostate cancer Title: Zometa reduces SRE, extends life

This extract can be found on http://PubMed.com, and is in the public domain.

On PubMed.com there will be a link to the full paper (often $30, sometimes free).

Any highlighting (except the title) is not by the author, but by Jim Marshall.

Jim is not a doctor.

This page was found on the Advanced Prostate Cancer Community for Australian men at http://advancedprost...lia.ipbhost.com.

The link is hard to remember.

An easier way to find it is to go to JimJimJimJim.com and click on Prostate.

That's the word Jim four times, no spaces, followed by .com.

If you need other help - to perhaps find someone to talk to or a local support group:

Click on the Contact Jim button at http://JimJimJimJim.com.

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...